Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial by Shaw, Alice T, Prof, Solomon, Benjamin J, Prof, Chiari, Rita, MD, Riely, Gregory J, MD, Besse, Benjamin, Prof, Soo, Ross A, MD, Kao, Steven, MBChB, Lin, Chia-Chi, MD, Bauer, Todd M, MD, Clancy, Jill S, BS, Thurm, Holger, MD, Martini, Jean-Francois, PhD, Peltz, Gerson, MD, Abbattista, Antonello, BSc, Li, Sherry, MS, Ou, Sai-Hong Ignatius, Prof

Get full text

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study by Solomon, Benjamin J, Prof, Besse, Benjamin, Prof, Bauer, Todd M, MD, Felip, Enriqueta, MD, Soo, Ross A, MD, Camidge, D Ross, Prof, Chiari, Rita, MD, Bearz, Alessandra, MD, Lin, Chia-Chi, MD, Gadgeel, Shirish M, Prof, Riely, Gregory J, MD, Tan, Eng Huat, MBBS, Seto, Takashi, Prof, James, Leonard P, MD, Clancy, Jill S, BS, Abbattista, Antonello, BSc, Martini, Jean-François, PhD, Chen, Joseph, PharmD, Peltz, Gerson, MD, Thurm, Holger, MD, Ou, Sai-Hong Ignatius, Prof, Shaw, Alice T, Prof

Get full text